Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Accured Expenses (2021 - 2025)

Krystal Biotech's Change in Accured Expenses history spans 5 years, with the latest figure at $5.8 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 22.68% year-over-year to $5.8 million; the TTM value through Dec 2025 reached $14.1 million, up 161.62%, while the annual FY2025 figure was $14.1 million, 161.62% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $5.8 million at Krystal Biotech, down from $5.9 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $7.5 million in Q4 2024 and bottomed at -$5.2 million in Q1 2024.
  • The 5-year median for Change in Accured Expenses is $2.0 million (2022), against an average of $1.6 million.
  • The largest annual shift saw Change in Accured Expenses skyrocketed 629.35% in 2022 before it tumbled 272.03% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at -$4.0 million in 2021, then soared by 153.64% to $2.2 million in 2022, then skyrocketed by 70.75% to $3.7 million in 2023, then soared by 103.18% to $7.5 million in 2024, then decreased by 22.68% to $5.8 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Change in Accured Expenses are $5.8 million (Q4 2025), $5.9 million (Q3 2025), and -$1.3 million (Q2 2025).